Development of Deep Learning Models for Detection of Neurodegenerative Diseases Using Speech - a Danish Language-based Artificial Intelligence Study (DetectAI)
Sponsor: Zealand University Hospital
Trial Details
| Condition | Dementia (Diagnosis), Alzheimer Dementia (AD), Vascular Dementia (VaD), Lewy Body Dementia (LBD), Frontotemporal Dementia (FTD), Mild Cognitive Impairment (MCI), Depression - Major Depressive Disorder, Stress, Cognitive Impairment |
| Intervention | Mini-mental State Examination; Addenbrooke's Cognitive Examination; Speech Task - Picture Description; Speech Task - Picture Recall; MRI; blood sampling; Depression screening; Somatic- and neurological examination; Speech Task - Picture Narrative |
| Status | Not_yet_recruiting |
| Participants | 440 |
| Est. Completion | 1 May 2028 |
| Last Updated | 5 May 2026 |
Primary Outcome
Model A: Primary measure is the AUC-ROC of the model in distinguishing between MCI and AD as well as between MCI and cognitively healthy control participants.
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: Model A (patient participants) * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling * A diagnosis of either MCI or AD, given at the SUH memory clinic within 6 months before enrollment Model A (cognitively healthy controls) * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling Model B: * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling Exclusion Criteria: Model A: Patients: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE score \< 16 * Concomitant diagnoses which are expected to influence cognitive impairment (eg. depression) * Patients unable to give consent * Patients with alcohol consumption \>21 standard alcohol units per week * Any history of speech or language impairment predating the current condition Cognitively healthy controls: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE \< 26 and ACE \< 90 * Clinical, laboratory, or neuroradiological findings that could affect cognitive functions * Known diseases which are expected to impair cognitive functions * Any history of speech or language impairment predating the current condition * Patients with alcohol consumption \>21 standard alcohol units per week. Model B: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE score \< 16 * Patients unable to give consent * Patients with concomitant psychosis or severe psychiatric comorbidities other than depression * Any history of speech or language impairment predating the current condition
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service